Drug Trial Radar · NCT03387085
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Last checked: Nov 20, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Mar 19, 2018
Primary completion
Sep 11, 2020
Study completion Jan 16, 2024
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or after previous SoC chemotherapy. Phase 2 will be based on Simon's two-stage optimal design.
Conditions
- Triple Negative Breast Cancer
Interventions
Aldoxorubicin HClDrug
Aldoxorubicin hydrochloride
N-803Biological
Recombinant human super agonist interleukin-15 (IL-15) complex
ETBX-011Biological
Ad5 \[E1-, E2b-\]-CEA
ETBX-051Biological
Ad5 \[E1-, E2b-\]-Brachyury vaccine
ETBX-061Biological
Ad5 \[E1-, E2b-\]-MUC1
GI-4000Biological
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
GI-6207Biological
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
GI-6301Biological
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
haNK for InfusionBiological
NK-92 \[CD16.158V, ER IL-2\]
avelumabBiological
Recombinant human anti-PD-L1 IgG1 monoclonal antibody
bevacizumabBiological
Recombinant human anti-VEGF IgG1 monoclonal
CapecitabineDrug
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
CisplatinDrug
cis-diamminedichloroplatinum(II)
CyclophosphamideDrug
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
5-FluorouracilDrug
5-fluoro-2,4 (1H,3H)-pyrimidinedione
LeucovorinDrug
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
nab-PaclitaxelDrug
Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
SBRTProcedure
Stereotactic Body Radiation Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.